<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Evaluation of sleep-disordered breathing in adult patients with neuromuscular and chest wall disorders
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Evaluation of sleep-disordered breathing in adult patients with neuromuscular and chest wall disorders
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Evaluation of sleep-disordered breathing in adult patients with neuromuscular and chest wall disorders
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Naomi R Kramer, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard P Millman, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Nicholas S Hill, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jeremy M Shefner, MD, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            M Safwan Badr, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Geraldine Finlay, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 01, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with neuromuscular  (
         <a class="graphic graphic_table graphicRef69167" href="/z/d/graphic/69167.html" rel="external">
          table 1
         </a>
         ) or chest wall disorders (eg, kyphoscoliosis) are at risk of developing sleep-disordered breathing (SDB), which, if left untreated, can be associated with significant morbidity [
         <a href="#rid1">
          1
         </a>
         ]. However, detection of SDB can be difficult in this population and relies upon clinician suspicion and heightened awareness of SDB as a complication of the underlying disorder.
        </p>
        <p>
         This topic will discuss the evaluation of patients with a known diagnosis of neuromuscular or chest wall disorders for potential underlying SDB. The evaluation of patients for suspected obstructive sleep apnea and central sleep apnea in the absence of neuromuscular or chest wall disorders are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7706.html" rel="external">
          "Clinical presentation and diagnosis of obstructive sleep apnea in adults"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7701.html" rel="external">
          "Central sleep apnea: Risk factors, clinical presentation, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3365542862">
         <span class="h1">
          SCOPE OF SLEEP-RELATED BREATHING DISORDERS
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with neuromuscular disorders (NMDs)  (
         <a class="graphic graphic_table graphicRef69167" href="/z/d/graphic/69167.html" rel="external">
          table 1
         </a>
         ) and chest wall abnormalities (eg, kyphoscoliosis), SDB is most often due to one or a combination of the following [
         <a href="#rid2">
          2-5
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Obstructive sleep apnea (OSA; a disorder characterized by obstructive apneas and hypopneas) – (See
         <a class="medical medical_review" href="/z/d/html/7706.html" rel="external">
          "Clinical presentation and diagnosis of obstructive sleep apnea in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nocturnal hypoventilation – (See
         <a class="medical medical_review" href="/z/d/html/5121.html" rel="external">
          "Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation", section on 'Nocturnal hypoventilation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         In patients with myotonic dystrophy, central sleep apnea can also be seen [
         <a href="#rid6">
          6-8
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5147.html" rel="external">
          "Myotonic dystrophy: Etiology, clinical features, and diagnosis", section on 'Respiratory function'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7699.html" rel="external">
          "Central sleep apnea: Pathogenesis"
         </a>
         .)
        </p>
        <p>
         In patients with NMDs, OSA and nocturnal hypoventilation are poorly understood but may relate to respiratory muscle weakness, reduced bulbar tone, anatomic factors (eg, large tongue), and possibly low lung volumes (which can effect upper airway area) [
         <a href="#rid9">
          9
         </a>
         ]. In patients with chest wall disorders, SDB has an unclear pathogenesis but may be due to a combination of respiratory muscle dysfunction, alterations in upper airway anatomy, and decreased lung and chest wall compliance.
        </p>
        <p class="headingAnchor" id="H3042538105">
         <span class="h1">
          IDENTIFYING AT-RISK PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         We have a low threshold to suspect SDB in patients with neuromuscular  (
         <a class="graphic graphic_table graphicRef69167" href="/z/d/graphic/69167.html" rel="external">
          table 1
         </a>
         ) and chest wall disorders where SDB is a known complication. This includes, but is not limited to, patients with amyotrophic lateral sclerosis (ALS), muscular dystrophy, kyphoscoliosis, diaphragmatic paralysis, or a history of poliomyelitis. In patients with neuromuscular and chest wall disorders, we adopt an approach of surveillance that promotes the early detection of SDB and prompts appropriate management before secondary complications of SDB occur (eg, hypertension, cardiovascular disease, chronic hypoventilation). (See
         <a class="local">
          'Components of surveillance'
         </a>
         below and
         <a class="local">
          'At-risk disorders'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1670912207">
         <span class="h2">
          Components of surveillance
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with neuromuscular or chest wall disorders, vigilant monitoring for evidence of SDB is important for early detection. Our general approach is the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         At the time of the original diagnosis and during follow-up visits, we inquire about sleepiness and fatigue and ask questions that may indicate underlying SDB or respiratory muscle weakness. Details of this evaluation are provided in the tables  (
         <a class="graphic graphic_table graphicRef86812" href="/z/d/graphic/86812.html" rel="external">
          table 2
         </a>
         and
         <a class="graphic graphic_table graphicRef55633" href="/z/d/graphic/55633.html" rel="external">
          table 3
         </a>
         ) and discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14892.html" rel="external">
          "Approach to the patient with excessive daytime sleepiness"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5121.html" rel="external">
          "Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If symptoms of SDB are present at the time of the original diagnosis or during follow-up, we proceed with evaluation for SDB (typically polysomnography [PSG]). (See
         <a class="local">
          'Patients with symptoms or signs of SDB'
         </a>
         below and
         <a class="local">
          'Diagnostic approach'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/7706.html" rel="external">
          "Clinical presentation and diagnosis of obstructive sleep apnea in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If respiratory muscle weakness is suspected on the basis of symptoms, we perform respiratory muscle strength testing; pulmonary function testing; and blood work, including complete blood count, bicarbonate level, electrocardiography, and arterial or venous blood gas analysis (to detect polycythemia, hypercarbia, and cor pulmonale). Based upon on the results of these objective tests, we may then proceed with PSG (See
         <a class="medical medical_review" href="/z/d/html/5121.html" rel="external">
          "Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation", section on 'Clinical manifestations'
         </a>
         and
         <a class="local">
          'Evidence of significant respiratory muscle weakness'
         </a>
         below and
         <a class="local">
          'Diagnostic approach'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         From a pragmatic standpoint, evaluation for SDB and respiratory muscle weakness may also occur in parallel since there is frequently overlap in the symptoms and distinguishing between SDB and respiratory muscle weakness may be difficult.
        </p>
        <p>
        </p>
        <p>
         There is no formal template for how often surveillance should occur, but it is generally tailored toward the nature of the underlying disorder, the speed at which it progresses (if at all), and the presence of symptoms at the time of the original diagnosis or during follow-up. Suggested surveillance for specific disorders are discussed in the sections below. (See
         <a class="local">
          'At-risk disorders'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1262498977">
         <span class="h2">
          At-risk disorders
         </span>
         <span class="headingEndMark">
          —
         </span>
         Common neuromuscular or chest wall disorders that are prone to developing SDB and appropriate surveillance timelines are discussed in this section.
        </p>
        <p class="headingAnchor" id="H1488522229">
         <span class="h3">
          Amyotrophic lateral sclerosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         ALS is the most common NMD affecting respiratory muscle function in adults. With progression comes an increased risk for developing SDB, particularly obstructive sleep apnea (OSA) and nocturnal hypoventilation [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
         For patients with ALS, serial assessment of respiratory function is typically performed every three months starting at the time of diagnosis. If the patient is diagnosed with respiratory muscle weakness and meets criteria  (
         <a class="graphic graphic_table graphicRef79606" href="/z/d/graphic/79606.html" rel="external">
          table 4
         </a>
         ), PSG is performed. Nocturnal oxygen desaturation correlates with nocturnal hypoventilation in this population but is insensitive and will miss approximately 30 percent of cases detected by transcutaneous capnography. Details regarding respiratory surveillance of patients with ALS are described separately. (See
         <a class="medical medical_review" href="/z/d/html/5129.html" rel="external">
          "Symptom-based management of amyotrophic lateral sclerosis", section on 'Sleep problems'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5129.html" rel="external">
          "Symptom-based management of amyotrophic lateral sclerosis", section on 'Pulmonary tests'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5121.html" rel="external">
          "Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation", section on 'Nocturnal hypoventilation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1276436664">
         <span class="h3">
          Muscular dystrophy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with Duchenne muscular dystrophy (DMD) or Becker muscular dystrophy may develop nocturnal hypoventilation due to respiratory dysfunction. In those with DMD, respiratory muscle weakness, and therefore SDB, may parallel the loss of ambulation in children or adolescents while patients with select variants of Becker muscular dystrophy may present later.
        </p>
        <p>
         Yearly monitoring of respiratory function is typical in patients with DMD or Becker muscular dystrophy. If the patient is diagnosed with respiratory muscle weakness and meets criteria  (
         <a class="graphic graphic_table graphicRef79606" href="/z/d/graphic/79606.html" rel="external">
          table 4
         </a>
         ), PSG is performed. Details regarding respiratory surveillance of patients with DMD are described separately. (See
         <a class="medical medical_review" href="/z/d/html/6181.html" rel="external">
          "Duchenne and Becker muscular dystrophy: Management and prognosis", section on 'Surveillance'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3011322571">
         <span class="h3">
          Kyphoscoliosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Kyphoscoliosis (KS) is associated with nocturnal hypoventilation and OSA, even in the absence of NMD [
         <a href="#rid11">
          11,12
         </a>
         ]. KS-related nocturnal oxygen desaturation and hypoventilation do not appear to directly correlate with the degree of KS, lung volumes, or ventilatory responsiveness. In contrast, daytime respiratory symptoms in KS are more common when the angle of the thoracic spinal deformity approaches 100 degrees. Such patients have become less common as surgeons have become more aggressive with spinal corrective surgery.
        </p>
        <p>
         For patients with KS, there is no known surveillance regimen that is followed for the detection of SDB. We rely upon symptoms and yearly pulmonary function tests (PFTs) and blood work to prompt sleep evaluation. (See
         <a class="medical medical_review" href="/z/d/html/4320.html" rel="external">
          "Chest wall diseases and restrictive physiology", section on 'Kyphosis and scoliosis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/91910.html" rel="external">
          "Scoliosis in the adult"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3112919515">
         <span class="h3">
          Diaphragm paralysis
         </span>
         <span class="headingEndMark">
          —
         </span>
         While unilateral diaphragm paralysis is more likely to present as an incidental radiologic finding, some patients may also have subtle symptoms of SDB, which should prompt a sleep evaluation. Although evidence of severe restriction or respiratory muscle weakness on PFT also warrant a sleep evaluation, severe derangement in pulmonary function is unusual with unilateral disease. (See
         <a class="medical medical_review" href="/z/d/html/16185.html" rel="external">
          "Diagnosis and management of nontraumatic unilateral diaphragmatic paralysis (complete or partial) in adults", section on 'Less common presentations'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16185.html" rel="external">
          "Diagnosis and management of nontraumatic unilateral diaphragmatic paralysis (complete or partial) in adults", section on 'Polysomnography'
         </a>
         .)
        </p>
        <p>
         In contrast, patients with bilateral diaphragm paralysis almost invariably have symptoms due to SDB with fragmented sleep and often nocturnal hypoventilation (eg, orthopnea) [
         <a href="#rid13">
          13
         </a>
         ]. These patients should have PSG at the time of diagnosis to detect SDB. (See
         <a class="medical medical_review" href="/z/d/html/5115.html" rel="external">
          "Diagnostic evaluation of adults with bilateral diaphragm paralysis", section on 'Clinical manifestations'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5115.html" rel="external">
          "Diagnostic evaluation of adults with bilateral diaphragm paralysis", section on 'Polysomnography'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1503847820">
         <span class="h3">
          Post-polio syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with a history of poliomyelitis who had initial involvement of respiratory, trunk, or bulbar muscles, particularly with associated scoliosis or vocal cord paralysis, are more likely than other poliomyelitis patients to develop SDB and gas exchange abnormalities during sleep [
         <a href="#rid14">
          14,15
         </a>
         ]. As the polio epidemics become more remote, polio survivors are becoming less common.
        </p>
        <p>
         There is no known optimal surveillance regimen for the detection of SDB or respiratory muscle dysfunction in this population. The post-polio syndrome progresses very slowly over years or even decades so we rely upon symptoms to prompt PSG. If initial PSG is unrevealing for SDB but symptoms persist, we may repeat PSG and/or perform yearly PFTs with respiratory muscle strength testing, which may prompt repeat sleep testing at a later time. (See
         <a class="medical medical_review" href="/z/d/html/5143.html" rel="external">
          "Poliomyelitis and post-polio syndrome", section on 'Clinical manifestations'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5143.html" rel="external">
          "Poliomyelitis and post-polio syndrome", section on 'Respiratory function'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H82574037">
         <span class="h2">
          Concomitant contributing risk factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         The presence of contributing factors for SDB in at-risk patients raises the suspicion for SDB and should prompt a search for clinical symptoms or signs of SDB.
        </p>
        <p>
         Contributing factors that we encounter in patients with neuromuscular and chest wall disorders include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Airflow obstruction – Patients with concomitant airflow obstruction tend to have greater gas exchange abnormalities and earlier-onset cor pulmonale associated with their SDB than do patients with normal airway resistance.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Obesity – Obesity increases the risk of certain forms of SDB, including OSA and obesity hypoventilation syndrome. (See
         <a class="medical medical_review" href="/z/d/html/7698.html" rel="external">
          "Clinical manifestations and diagnosis of obesity hypoventilation syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Left ventricle impairment – Some NMDs, such as DMD and myotonic muscular dystrophy, may be associated with cardiomyopathy [
         <a href="#rid16">
          16,17
         </a>
         ]. Left ventricle impairment, particularly if associated with Cheyne-Stokes respiration, may be associated with SDB and contributes to nocturnal oxygen desaturation and sleep fragmentation [
         <a href="#rid18">
          18,19
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7705.html" rel="external">
          "Obstructive sleep apnea and cardiovascular disease in adults", section on 'Cardiovascular events'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Others – Other risk factors for OSA are described separately. (See
         <a class="medical medical_review" href="/z/d/html/7706.html" rel="external">
          "Clinical presentation and diagnosis of obstructive sleep apnea in adults", section on 'Risk factors and associated conditions'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          PATIENT SELECTION FOR SLEEP EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suspect SDB in patients with neuromuscular or chest wall disorders who have the following  (
         <a class="graphic graphic_table graphicRef79606" href="/z/d/graphic/79606.html" rel="external">
          table 4
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef143003" href="/z/d/graphic/143003.html" rel="external">
          algorithm 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Symptoms or signs of SDB – (See
         <a class="local">
          'Patients with symptoms or signs of SDB'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Evidence of respiratory muscle weakness – (See
         <a class="local">
          'Evidence of significant respiratory muscle weakness'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Unexplained cor pulmonale, polycythemia, or elevated serum bicarbonate – (See
         <a class="local">
          'Unexplained cor pulmonale, polycythemia, hypercarbia'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         These criteria are a mix of clinical and physiologic factors that are typically present in patients with neuromuscular or chest wall disorders who have undergone an evaluation for respiratory muscle weakness. (See
         <a class="local">
          'Identifying at-risk patients'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/5121.html" rel="external">
          "Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3333546111">
         <span class="h2">
          Patients with symptoms or signs of SDB
         </span>
         <span class="headingEndMark">
          —
         </span>
         For any patient with a neuromuscular or chest wall disorder who has symptoms of SDB, we perform polysomnography (PSG). (See
         <a class="local">
          'Diagnostic approach'
         </a>
         below.)
        </p>
        <p>
         Classic symptoms of SDB are listed in the table  (
         <a class="graphic graphic_table graphicRef55633" href="/z/d/graphic/55633.html" rel="external">
          table 3
         </a>
         ) and are described in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7706.html" rel="external">
          "Clinical presentation and diagnosis of obstructive sleep apnea in adults", section on 'Clinical features'
         </a>
         .)
        </p>
        <p>
         Even when pulmonary dysfunction is severe, dyspnea is often lacking in patients with NMD, probably because exercise capacity is limited by involvement of nonrespiratory muscles, thereby reducing demand on respiratory muscles.
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Evidence of significant respiratory muscle weakness
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pulmonary function tests (PFTs) that include respiratory muscle strength testing and venous or arterial blood gas analysis is typically performed during evaluation for suspected respiratory muscle weakness and provides clues to possible coexisting SDB. If the criteria listed on the table are met  (
         <a class="graphic graphic_table graphicRef79606" href="/z/d/graphic/79606.html" rel="external">
          table 4
         </a>
         ), we perform PSG. (See
         <a class="local">
          'Diagnostic approach'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2680845194">
         <span class="h3">
          Abnormal gas exchange
         </span>
         <span class="headingEndMark">
          —
         </span>
         Evidence of even mild daytime gas exchange abnormalities should prompt diagnostic sleep evaluation. This is based upon the premise that patients with daytime hypercapnia (eg, arterial carbon dioxide pressure &gt;45 mmHg [6 kPa]) and/or hypoxemia (eg, peripheral pulse oximetry &lt;92 percent in the absence of another etiology) frequently have further deterioration of gas exchange during sleep. The most severe nocturnal oxygen desaturation is seen in those with cor pulmonale, polycythemia, and daytime systemic hypertension. (See
         <a class="medical medical_review" href="/z/d/html/5121.html" rel="external">
          "Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation", section on 'Arterial blood gas analysis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2727171366">
         <span class="h3">
          Pulmonary function abnormalities
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with evidence of significantly reduced respiratory muscle strength (eg, a maximal inspiratory pressure &lt;60 percent of predicted) or severe restriction due to their NMD (eg, forced vital capacity &lt;50 percent predicted), should have a formal sleep study since they are likely to have significant sleep-related desaturation and gas exchange abnormalities [
         <a href="#rid20">
          20-24
         </a>
         ]. The approach to interpreting PFTs in patients with neuromuscular weakness is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5121.html" rel="external">
          "Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation", section on 'Pulmonary function testing'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5121.html" rel="external">
          "Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation", section on 'Respiratory muscle strength testing'
         </a>
         .)
        </p>
        <p>
         As a general rule of thumb, if patients are too weak to perform PFTs as part of their respiratory muscle weakness evaluation, SDB is likely present and should prompt PSG. (See
         <a class="local">
          'Diagnostic approach'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2836098169">
         <span class="h2">
          Unexplained cor pulmonale, polycythemia, hypercarbia
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with neuromuscular or chest wall disorders who have unexplained cor pulmonale, polycythemia, or hypercarbia, we typically perform PSG. (See
         <a class="local">
          'Diagnostic approach'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          DIAGNOSTIC APPROACH
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with neuromuscular or chest wall disorder in whom SDB is suspected, we prefer formal sleep testing with in-laboratory polysomnography (PSG). PSG is our preferred test since it is capable of detecting all important and complex sleep-related respiratory events that are common in this population (see
         <a class="local">
          'Polysomnography'
         </a>
         below). While home sleep apnea testing (HSAT) is an option and may be the only third party-covered option available to patients, HSAT often misses many clinically important respiratory events during sleep in this population. Oximetry is not an adequate test to screen or diagnose SDB. (See
         <a class="local">
          'Other studies'
         </a>
         below.)
        </p>
        <p>
         The initial evaluation of patients suspected of having SDB should be performed by clinicians with experience in pulmonary, neurology, and sleep medicine. In some patients, if studies are equivocal or negative but the suspicion for SDB remains high, patients should be referred to a center experienced in the management of these patients with an accredited sleep laboratory. If the initial testing is negative but clinical suspicion is high, repeat testing may be needed, particularly if the disease progresses.
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Polysomnography
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with neuromuscular and chest wall disorders, PSG is currently considered the "gold standard" for the diagnosis of SDB. Monitoring of multiple channels with PSG allows full assessment of possible respiratory and nonrespiratory sleep disorders that can commonly coexist in patients with NMDs. However, some patients with advanced NMD may not be good candidates for in-laboratory PSG because of difficulty accommodating their personal needs; in such cases, consideration of HSAT may be needed, with an awareness of the limitations. (See
         <a class="local">
          'Other studies'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/7694.html" rel="external">
          "Home sleep apnea testing for obstructive sleep apnea in adults"
         </a>
         .)
        </p>
        <p>
         Medicare guidelines do not require a sleep study to initiate noninvasive ventilation (NIV) in patients with NMD, and there may be circumstances that make it difficult for patients to undergo in-laboratory PSG when empirical initiation without a sleep study may be a more practical option (distance from a sleep lab, delays in scheduling a sleep study in a rapidly deteriorating patient, or physical or other limitations).
        </p>
        <p>
         One essential part of PSG assessment is to document abnormalities of gas exchange during sleep. Oxygenation is easily assessed using bedside pulse oximetry to measure peripheral oxygen saturation (see
         <a class="medical medical_review" href="/z/d/html/1612.html" rel="external">
          "Pulse oximetry"
         </a>
         ). When available, some experts also include some form of carbon dioxide (CO
         <sub>
          2
         </sub>
         ) monitoring to support a diagnosis of hypoventilation during sleep, especially when NIV is being concurrently planned. While obtaining arterial or venous blood gases at the beginning and end of the sleep study could address this issue, it is not practical since such analysis is
         <strong>
          not
         </strong>
         universally available. More practical options include monitoring transcutaneous CO
         <sub>
          2
         </sub>
         (tcCO
         <sub>
          2
         </sub>
         ) and end-tidal CO
         <sub>
          2
         </sub>
         (PETCO
         <sub>
          2
         </sub>
         ), neither of which are universally available.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         TcCO
         <sub>
          2
         </sub>
         monitoring using the latest equipment appears to be reasonably accurate [
         <a href="#rid10">
          10,25,26
         </a>
         ] and is our preferred option in adults when available. When combined with oximetry, tcCO
         <sub>
          2
         </sub>
         may be more sensitive than nocturnal oximetry alone in detecting nocturnal hypoventilation [
         <a href="#rid27">
          27
         </a>
         ]. It is particularly useful for patients with NMD who cannot undergo PSG, need to be started on NIV as an outpatient, and are in situations where venous or arterial blood gases are not easy to obtain. (See
         <a class="medical medical_review" href="/z/d/html/99553.html" rel="external">
          "Polysomnography in the evaluation of sleep-disordered breathing in adults", section on 'Ventilation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         PETCO
         <sub>
          2
         </sub>
         monitoring is not typically used in adults but may be more useful in children undergoing PSG [
         <a href="#rid28">
          28-30
         </a>
         ]. Data suggest that PETCO
         <sub>
          2
         </sub>
         does not adequately reflect arterial values in adults and may be inaccurate in patients with significant nasal obstruction or underlying pulmonary disease with increased dead space, which can lead to an underestimation of the arterial CO
         <sub>
          2
         </sub>
         level [
         <a href="#rid31">
          31
         </a>
         ]. Also, PETCO
         <sub>
          2
         </sub>
         may not provide accurate data when supplemental oxygen is used or during use of continuous positive airway pressure (PAP) or NIV (ie, mask leaks may dilute exhaled gas). (See
         <a class="medical medical_review" href="/z/d/html/6363.html" rel="external">
          "Evaluation of suspected obstructive sleep apnea in children"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Further details on CO
         <sub>
          2
         </sub>
         monitoring during sleep are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/5118.html" rel="external">
          "Noninvasive ventilation in adults with chronic respiratory failure from neuromuscular and chest wall diseases: Practical aspects of initiation", section on 'Baseline measurements, oxygenation, and gas exchange monitoring'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/99553.html" rel="external">
          "Polysomnography in the evaluation of sleep-disordered breathing in adults", section on 'Ventilation'
         </a>
         .)
        </p>
        <p>
         Esophageal pressure monitoring during PSG is not yet considered standard but may be helpful in distinguishing central versus obstructive apneas because it offers a sensitive way of detecting intrathoracic pressure swings related to respiratory effort. Such monitoring is also particularly useful in detecting the upper airway resistance syndrome, which is characterized by subtle increases in respiratory effort that are not manifested by changes in air flow but are associated with arousal and sleep fragmentation [
         <a href="#rid32">
          32
         </a>
         ]. However, it requires placement of an esophageal manometry balloon. (See
         <a class="medical medical_review" href="/z/d/html/7706.html" rel="external">
          "Clinical presentation and diagnosis of obstructive sleep apnea in adults", section on 'Upper airway resistance syndrome'
         </a>
         .)
        </p>
        <p>
         Further details on the components of PSG and its value in the diagnosis of complex sleep disorders are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7696.html" rel="external">
          "Overview of polysomnography in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/99553.html" rel="external">
          "Polysomnography in the evaluation of sleep-disordered breathing in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7706.html" rel="external">
          "Clinical presentation and diagnosis of obstructive sleep apnea in adults", section on 'Polysomnography'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H89818652">
         <span class="h2">
          Other studies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other studies include HSAT and overnight oximetry. Neither test alone is sufficient to fully evaluate complex SDB, which can occur in patients with neuromuscular and chest wall disorders. If there is a strong clinical suspicion of SDB or otherwise unexplained excessive daytime sleepiness but oximetry or HSAT is negative, full PSG should still be obtained [
         <a href="#rid33">
          33,34
         </a>
         ].
        </p>
        <p>
         HSAT with four or more channels (eg, heart rate, air flow, chest movement, and oximetry) can detect moderate to severe obstructive sleep apnea (OSA). However, the severity of sleep apnea may be underestimated and mild disease may be missed entirely. In addition, central events, sleep disruption or fragmentation, hypoventilation, and respiratory effort-related arousals, which can all complicate sleep in patients with neuromuscular or chest wall disorders, are not adequately assessed by HSAT. (See
         <a class="medical medical_review" href="/z/d/html/7694.html" rel="external">
          "Home sleep apnea testing for obstructive sleep apnea in adults"
         </a>
         .)
        </p>
        <p>
         Overnight oximetry alone may be used to screen for oxygen desaturation associated with severe nocturnal hypoventilation in patients with neuromuscular and chest wall disorders. However, oximetry may underestimate the degree of sleep apnea and does not adequately exclude sleep apnea [
         <a href="#rid35">
          35-38
         </a>
         ]. In addition, oximetry may have low sensitivity in detecting OSA in patients receiving supplemental oxygen.
        </p>
        <p>
         Oximetry is helpful in screening for residual oxygen desaturation in patients who have been started on nocturnal NIV without evaluation in a sleep laboratory. Oximetry is required as data downloaded from the PAP device does not provide information about oxygen saturation, which can still be low in patients with hypoventilation despite adequate treatment of the sleep disorder. (See
         <a class="medical medical_review" href="/z/d/html/5118.html" rel="external">
          "Noninvasive ventilation in adults with chronic respiratory failure from neuromuscular and chest wall diseases: Practical aspects of initiation", section on 'Follow-up (adaptation phase)'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H509797471">
         <span class="h2">
          Diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of OSA, central sleep apnea, and nocturnal hypoventilation are provided separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7706.html" rel="external">
          "Clinical presentation and diagnosis of obstructive sleep apnea in adults", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7701.html" rel="external">
          "Central sleep apnea: Risk factors, clinical presentation, and diagnosis", section on 'Diagnostic criteria'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5121.html" rel="external">
          "Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation", section on 'Arterial blood gas analysis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2871559457">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/113310.html" rel="external">
          "Society guideline links: Sleep-related breathing disorders in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Scope
         </strong>
         – Sleep-disordered breathing (SDB) is common in patients with neuromuscular or chest wall disorders and, if untreated, can be a significant cause of morbidity and mortality. SDB in this population is most often due to obstructive sleep apnea (OSA) and/or nocturnal hypoventilation. Central sleep apnea (CSA) is less common. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          At risk patients
         </strong>
         – We have a low threshold to suspect SDB in patients with neuromuscular and chest wall disorders in whom SDB is a known complication.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         This includes but is not limited to patients with amyotrophic lateral sclerosis, muscular dystrophy, kyphoscoliosis, diaphragmatic paralysis, or a history of poliomyelitis (especially with initial respiratory, trunk, or bulbar involvement)  (
         <a class="graphic graphic_table graphicRef69167" href="/z/d/graphic/69167.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Identifying at-risk patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         At the time of diagnosis and periodic follow-up visits, we inquire about sleepiness and fatigue and ask questions that may indicate underlying SDB  (
         <a class="graphic graphic_table graphicRef86812" href="/z/d/graphic/86812.html" rel="external">
          table 2
         </a>
         and
         <a class="graphic graphic_table graphicRef55633" href="/z/d/graphic/55633.html" rel="external">
          table 3
         </a>
         ) or respiratory muscle weakness. From a pragmatic standpoint, evaluation for SDB (ie, polysomnography [PSG]) and respiratory weakness (respiratory muscle strength testing, pulmonary function testing, complete blood count, bicarbonate level, electrocardiography, and arterial or venous blood gas analysis) may also occur in parallel since there is frequently overlap in the symptoms, and distinguishing between SDB and respiratory muscle weakness may be difficult. Details of this evaluation and frequency of surveillance are provided separately. (See
         <a class="local">
          'Components of surveillance'
         </a>
         above and
         <a class="local">
          'At-risk disorders'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/14892.html" rel="external">
          "Approach to the patient with excessive daytime sleepiness"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5121.html" rel="external">
          "Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patient selection
         </strong>
         – We suspect SDB and proceed with PSG in patients with neuromuscular and chest wall disorders who have the following  (
         <a class="graphic graphic_table graphicRef79606" href="/z/d/graphic/79606.html" rel="external">
          table 4
         </a>
         ) (See
         <a class="local">
          'Patient selection for sleep evaluation'
         </a>
         above.):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Symptoms or signs of SDB  (
         <a class="graphic graphic_table graphicRef55633" href="/z/d/graphic/55633.html" rel="external">
          table 3
         </a>
         ) – (See
         <a class="local">
          'Patients with symptoms or signs of SDB'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7706.html" rel="external">
          "Clinical presentation and diagnosis of obstructive sleep apnea in adults", section on 'Clinical features'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with evidence of significant respiratory muscle weakness, such as the following (see
         <a class="local">
          'Evidence of significant respiratory muscle weakness'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/5121.html" rel="external">
          "Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation", section on 'Diagnostic evaluation'
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Abnormal gas exchange including daytime hypoxemia (eg, peripheral oxygen saturation &lt;92 percent) or hypercapnia (eg, arterial carbon dioxide tension &gt;45 mmHg [6 kPa]). (See
         <a class="local">
          'Evidence of significant respiratory muscle weakness'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Maximal inspiratory pressure &lt;60 percent predicted or severe restrictive lung function (eg, forced vital capacity &lt;50 percent predicted). (See
         <a class="local">
          'Pulmonary function abnormalities'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with unexplained cor pulmonale, polycythemia, or hypercarbia – (See
         <a class="local">
          'Unexplained cor pulmonale, polycythemia, hypercarbia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnostic approach
         </strong>
         – For patients with neuromuscular or chest wall disorders in whom SDB is suspected, we perform formal sleep testing with in-laboratory PSG. In-laboratory PSG is our preferred test since it is capable of detecting all the complex sleep disturbances that are common in this population, many of which are likely to be missed on home sleep apnea testing (HSAT). (See
         <a class="local">
          'Diagnostic approach'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         While HSAT can detect moderate or severe OSA, it cannot adequately detect other important respiratory events that can occur in this population, such as mild OSA, central apnea events, sleep disruption or fragmentation, hypoventilation, and respiratory effort-related arousals. Oximetry is not an adequate test to screen or diagnose SDB but may be used to detect residual nocturnal desaturation events after diagnosis when patients are on noninvasive ventilation. (See
         <a class="local">
          'Other studies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis of OSA, CSA, and nocturnal hypoventilation are provided separately.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7706.html" rel="external">
          "Clinical presentation and diagnosis of obstructive sleep apnea in adults", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7701.html" rel="external">
          "Central sleep apnea: Risk factors, clinical presentation, and diagnosis", section on 'Diagnostic criteria'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5121.html" rel="external">
          "Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation", section on 'Arterial blood gas analysis'
         </a>
         .)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Perrin C, Unterborn JN, Ambrosio CD, Hill NS. Pulmonary complications of chronic neuromuscular diseases and their management. Muscle Nerve 2004; 29:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shneerson JM. Respiration during sleep in neuromuscular and thoracic cage disorders. Monaldi Arch Chest Dis 2004; 61:44.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bourke SC, Gibson GJ. Sleep and breathing in neuromuscular disease. Eur Respir J 2002; 19:1194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guilleminault C, Shergill RP. Sleep-disordered Breathing in Neuromuscular Disease. Curr Treat Options Neurol 2002; 4:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krachman SL, Criner GJ. Sleep and long-term ventilation. Respir Care Clin N Am 2002; 8:611.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cirignotta F, Mondini S, Zucconi M, et al. Sleep-related breathing impairment in myotonic dystrophy. J Neurol 1987; 235:80.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith PE, Edwards RH, Calverley PM. Ventilation and breathing pattern during sleep in Duchenne muscular dystrophy. Chest 1989; 96:1346.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith PE, Calverley PM, Edwards RH, et al. Practical problems in the respiratory care of patients with muscular dystrophy. N Engl J Med 1987; 316:1197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Appelberg J, Nordahl G, Janson C. Lung volume and its correlation to nocturnal apnoea and desaturation. Respir Med 2000; 94:233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boentert M, Glatz C, Helmle C, et al. Prevalence of sleep apnoea and capnographic detection of nocturnal hypoventilation in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2018; 89:418.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ellis ER, Grunstein RR, Chan S, et al. Noninvasive ventilatory support during sleep improves respiratory failure in kyphoscoliosis. Chest 1988; 94:811.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mezon BL, West P, Israels J, Kryger M. Sleep breathing abnormalities in kyphoscoliosis. Am Rev Respir Dis 1980; 122:617.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steier J, Jolley CJ, Seymour J, et al. Screening for sleep-disordered breathing in neuromuscular disease using a questionnaire for symptoms associated with diaphragm paralysis. Eur Respir J 2011; 37:400.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dolmage TE, Avendano MA, Goldstein RS. Respiratory function during wakefulness and sleep among survivors of respiratory and non-respiratory poliomyelitis. Eur Respir J 1992; 5:864.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steljes DG, Kryger MH, Kirk BW, Millar TW. Sleep in postpolio syndrome. Chest 1990; 98:133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verhaert D, Richards K, Rafael-Fortney JA, Raman SV. Cardiac involvement in patients with muscular dystrophies: magnetic resonance imaging phenotype and genotypic considerations. Circ Cardiovasc Imaging 2011; 4:67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feingold B, Mahle WT, Auerbach S, et al. Management of Cardiac Involvement Associated With Neuromuscular Diseases: A Scientific Statement From the American Heart Association. Circulation 2017; 136:e200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bradley TD. Right and left ventricular functional impairment and sleep apnea. Clin Chest Med 1992; 13:459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamashiro Y, Kryger MH. Review: sleep in heart failure. Sleep 1993; 16:513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ragette R, Mellies U, Schwake C, et al. Patterns and predictors of sleep disordered breathing in primary myopathies. Thorax 2002; 57:724.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gay PC, Westbrook PR, Daube JR, et al. Effects of alterations in pulmonary function and sleep variables on survival in patients with amyotrophic lateral sclerosis. Mayo Clin Proc 1991; 66:686.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Unterborn JN, Hill NS. Options for mechanical ventilation in neuromuscular diseases. Clin Chest Med 1994; 15:765.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Braun NM, Arora NS, Rochester DF. Respiratory muscle and pulmonary function in polymyositis and other proximal myopathies. Thorax 1983; 38:616.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mendoza M, Gelinas DF, Moore DH, Miller RG. A comparison of maximal inspiratory pressure and forced vital capacity as potential criteria for initiating non-invasive ventilation in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2007; 8:106.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aarrestad S, Tollefsen E, Kleiven AL, et al. Validity of transcutaneous PCO2 in monitoring chronic hypoventilation treated with non-invasive ventilation. Respir Med 2016; 112:112.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Storre JH, Magnet FS, Dreher M, Windisch W. Transcutaneous monitoring as a replacement for arterial PCO(2) monitoring during nocturnal non-invasive ventilation. Respir Med 2011; 105:143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kwok K, Bush A, Simonds A, Tan H. Is overnight oxycapnography sufficient as a screening test in identifying patients with neuromuscular diseases (NMD) who need ventilatory support? ERJ Open Res 2019; 5 (Suppl 3):P138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosen CL, D'Andrea L, Haddad GG. Adult criteria for obstructive sleep apnea do not identify children with serious obstruction. Am Rev Respir Dis 1992; 146:1231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marcus CL, Omlin KJ, Basinki DJ, et al. Normal polysomnographic values for children and adolescents. Am Rev Respir Dis 1992; 146:1235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kotterba S, Patzold T, Malin JP, et al. Respiratory monitoring in neuromuscular disease - capnography as an additional tool? Clin Neurol Neurosurg 2001; 103:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanders MH, Kern NB, Costantino JP, et al. Accuracy of end-tidal and transcutaneous PCO2 monitoring during sleep. Chest 1994; 106:472.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guilleminault C, Stoohs R, Clerk A, et al. A cause of excessive daytime sleepiness. The upper airway resistance syndrome. Chest 1993; 104:781.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Westenberg JN, Petrof BJ, Noel F, et al. Validation of home portable monitoring for the diagnosis of sleep-disordered breathing in adolescents and adults with neuromuscular disorders. J Clin Sleep Med 2021; 17:1579.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hunasikatti M. Home portable monitoring for the diagnosis of sleep-disordered breathing in adolescents and adults with neuromuscular disorders: not yet ready for prime time. J Clin Sleep Med 2021; 17:2565.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meyer TJ, Eveloff SE, Kline LR, Millman RP. One negative polysomnogram does not exclude obstructive sleep apnea. Chest 1993; 103:756.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonsignore G, Marrone O, Macaluso C, et al. Validation of oximetry as a screening test for obstructive sleep apnoea syndrome. Eur Respir J Suppl 1990; 11:542s.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Douglas NJ, Thomas S, Jan MA. Clinical value of polysomnography. Lancet 1992; 339:347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams AJ, Yu G, Santiago S, Stein M. Screening for sleep apnea using pulse oximetry and a clinical score. Chest 1991; 100:631.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 7711 Version 24.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14694494" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Pulmonary complications of chronic neuromuscular diseases and their management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15366336" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Respiration during sleep in neuromuscular and thoracic cage disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12108875" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Sleep and breathing in neuromuscular disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11827642" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Sleep-disordered Breathing in Neuromuscular Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12602418" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Sleep and long-term ventilation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3430195" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Sleep-related breathing impairment in myotonic dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2582842" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Ventilation and breathing pattern during sleep in Duchenne muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3553943" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Practical problems in the respiratory care of patients with muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10783934" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Lung volume and its correlation to nocturnal apnoea and desaturation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29054915" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Prevalence of sleep apnoea and capnographic detection of nocturnal hypoventilation in amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3139373" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Noninvasive ventilatory support during sleep improves respiratory failure in kyphoscoliosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7436128" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Sleep breathing abnormalities in kyphoscoliosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20595146" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Screening for sleep-disordered breathing in neuromuscular disease using a questionnaire for symptoms associated with diaphragm paralysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1499712" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Respiratory function during wakefulness and sleep among survivors of respiratory and non-respiratory poliomyelitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2361379" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Sleep in postpolio syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21245364" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Cardiac involvement in patients with muscular dystrophies: magnetic resonance imaging phenotype and genotypic considerations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28838934" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Management of Cardiac Involvement Associated With Neuromuscular Diseases: A Scientific Statement From the American Heart Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1521413" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Right and left ventricular functional impairment and sleep apnea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8235235" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Review: sleep in heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12149535" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Patterns and predictors of sleep disordered breathing in primary myopathies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2072756" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Effects of alterations in pulmonary function and sleep variables on survival in patients with amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7867290" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Options for mechanical ventilation in neuromuscular diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6412385" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Respiratory muscle and pulmonary function in polymyositis and other proximal myopathies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17453639" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : A comparison of maximal inspiratory pressure and forced vital capacity as potential criteria for initiating non-invasive ventilation in amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26874895" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Validity of transcutaneous PCO2 in monitoring chronic hypoventilation treated with non-invasive ventilation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21030230" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Transcutaneous monitoring as a replacement for arterial PCO(2) monitoring during nocturnal non-invasive ventilation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Is overnight oxycapnography sufficient as a screening test in identifying patients with neuromuscular diseases (NMD) who need ventilatory support?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1443876" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Adult criteria for obstructive sleep apnea do not identify children with serious obstruction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1443877" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Normal polysomnographic values for children and adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11516550" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Respiratory monitoring in neuromuscular disease - capnography as an additional tool?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7774323" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Accuracy of end-tidal and transcutaneous PCO2 monitoring during sleep.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8365289" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : A cause of excessive daytime sleepiness. The upper airway resistance syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33739260" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Validation of home portable monitoring for the diagnosis of sleep-disordered breathing in adolescents and adults with neuromuscular disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34534070" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Home portable monitoring for the diagnosis of sleep-disordered breathing in adolescents and adults with neuromuscular disorders: not yet ready for prime time.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8449064" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : One negative polysomnogram does not exclude obstructive sleep apnea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2278624" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Validation of oximetry as a screening test for obstructive sleep apnoea syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1346422" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Clinical value of polysomnography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1889245" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Screening for sleep apnea using pulse oximetry and a clinical score.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
